Torrid expects full year fiscal 2026 net sales between $940M and $960M, Adjusted EBITDA between $65M and $75M, and capital expenditures between $8 million and $10 million.
Bullish
Torrid delivered $1B in sales and exceeded Adjusted EBITDA guidance for fiscal 2025, driven by strategic store optimization, new sub-brands, and a strong operational foundation for future customer growth.
Bearish
Torrid experienced a 14.3% net sales decrease and a $13M net cash outflow from operations for fiscal 2025, while facing risks from changing consumer spending and GLP-1 medication use.